Src is a non-receptor tyrosine kinase involved in the crosstalk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration and tumorigenesis. Increased Src activity has been reported in many types of human cancer including gastric cancer. Therefore, this factor has been identified as a promising therapeutic target for cancer treatments, and targeting Src in gastric cancer is predicted to have potent effects. We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor saracatinib (AZD0530) alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model. Among 10 gastric cancer cell lines, saracatinib specifically inhibited the growth and migration/invasion of SNU216 and NCI-N87 cells. Saracatinib blocked the Src/FAK, HER family and oncogenic signaling pathways, and it induced G1 arrest and apoptosis in SNU216 and NCI-N87 cells. Apoptosis required induction of the pro-apoptotic BCL2 family member, Bim. Knockdown of Bim using siRNA decreased apoptosis induced by treatment with saracatinib, suggesting that Bim has an important role in saracatinib-induced apoptosis.
Introduction
Src belongs to a family of non-receptor protein tyrosine kinases (SFKs).Activation of this factor can be regulated by interaction with focal adhesion kinase (FAK) and Crk-associated substrate (CAS). Src is involved in the crosstalk between many signaling pathways, including the integrin/FAK, epidermal growth factor receptor (EGFR), Ras/Raf/MEK, PI3K/AKT, and JAK/STAT pathways, that promote cell proliferation, adhesion, invasion, migration, metastasis, and tumorigenesis (1) (2) . A previous analysis found that 20% of human breast cancers overexpress both Src and EGFR, suggesting the involvement of Src in the EGFR signaling pathway (3) . Another study found that Src activation is required for EGF-induced integrin-mediated migration and metastasis. This finding is indicative of crosstalk in the Src/EGFR/integrin pathway and demonstrates that Src is a key regulator of signal transduction (4) (5) .
Elevation of Src expression and catalytic activity has been reported in a number of human cancers including lung, skin, colon, breast, ovarian, and head and neck malignancies (6) . Src activity is also increased in gastric cancer (7) (8) . The presence of activated Src in gastric cancer along with the role of this factor in cancer cell proliferation and metastasis raise the possibility that Src is a promising target for treating gastric cancer. However, the role of Src as a therapeutic target has not been widely studied.
Saracatinib (AZD0530) is a potent, orally administered small molecule that inhibits Src by blocking the ATP-binding site of Src kinases. The anti-proliferative activity of saracatinib has been reported in several human cancer cell lines and xenograft models (9). Together with an ER blockade, saracatinib was found to be effective in ER-positive breast cancer cell lines and a xenograft model (10). Saracatinib also exerted antitumor effects in a preclinical model of colorectal cancer,suggesting that increased activation of the Src pathway is associated with sensitivity to saracatinib (11). However, it is not known which biomarkers can predict the sensitivity of solid tumors to Src inhibitors. Author Manuscript Published OnlineFirst on November 9, 2012; DOI: 10.1158/1535-7163.MCT-12-0109 7 drug, MTT solution was added to each well and the cells were incubated for 4h at 37℃ before the medium was removed. Next, DMSO was added to each well and the plates were shaken for 30 min at room temperature. Cell viability was determined by measuring the absorbance of all wells at 540 nm with a microplate reader (Versa Max; Molecular Devices, Sunnyvale, CA, USA). Six replicate wells were used for each analysis and at least three independent experiments were conducted. Data points shown represent the mean while bars represent the standard deviation (SD).
To evaluate the effects of saracatinib administered in conjunction with other chemotherapeutic agents (5-FU or cisplatin), the cells were treated with serial dilutions of each drug alone or with a combination of saracatinib with either chemotherapeutic agent at a fixed ratio corresponding to the specificl IC 50 of each drug. After 72 h of drug exposure, cell proliferation was measured using an MTT assay as described above. Any synergistic effects resulting from co-treatment with the compounds were measured using the methods described by Chou and Talalay (16) (17) . Analysis of the median effect was conducted using Calcusyn software (Biosoft) to determine the combination index values (CI > 1: antagonistic effect, CI = 1:additive effect, and CI <1: synergistic effect).
Migration and invasion assay
SNU216 cells were seeded in a 6-well plate (4ⅹ10 5 cells per well). After 24h, the cell monolayers were scratched with a yellow tip. The plates were washed with phosphate buffered saline, and the cells were then incubated with medium alone or medium containing 1μmol/L of saracatinib. After 24h, the plates were examined by light microscopy to monitor resealing of the cell monolayer.
The cell invasion was measured using a Cytoselect 24-well cell invasion assay kit (Cell Biolabs, Inc., San Diego, CA, USA). This kit included polycarbonate membrane inserts (8μm pore size). The upper surface of the insert membrane was coated with a uniform layer of dried murine laminin I matrix.
SNU216 cells were serum-starved for 24 h. Next, a cell suspension containing 4ⅹ10 5 cells/mL of serum free media alone or serum free media with 1μmol/L of saracatinib were added to the inside of
Annexin V Binding Assay for Apoptosis
After the cells were exposed to saracatinib or lapatinib, the degree of apoptosis was assessed using the Annexin V binding assay according to the protocols of the manufacturer (BD PharMingen). The harvested cell suspension was then incubated with Annexin V for 15 min at room temperature in the dark and then analyzed by flow cytometry.
Short Interfering RNA Knockdown
Short interfering RNA (siRNA) specific for Bim, and nonspecific controls were purchased from Qiagen (Hilden, Germany). Transfection procedures were conducted using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions at a final concentration of 40 nmol/L.
In Vivo Studies
Animal experiments were carried out in the animal facility of the Seoul National University in 
Statistical Analysis
All experiments were conducted in duplicate or triplicate and repeated at least twice. SE was used when calculating IC50 values using SigmaPlot version 9.0. All results that are presented in the graph were expressed as bars, ± SD. The statistical significance of the results was analyzed using an unpaired Student's t-test. P-values < 0.05 were considered to be statistically significant. 
Results

SNU216 and NCI-N87 gastric cancer cells were sensitive to saracatinib.
We examined the inhibitory effects of saracatinib on the growth of 10 gastric cancer cell lines (SNU-1, 5, 16, 216, 601, 620, 638, 668, 719 and NCI-N87). The molecular alteration of these cells was previously reported (19). SNU216 and NCI-N87 cells were sensitive to saracatinib at IC 50 values lower than 1 μmol/L ( Table 1 ). As shown in Fig. 1A , saracatinib also exerted anti-migratory (left) and anti-invasive effects (right; figure and graph) in SNU216 cells.
We next measured the basal expression levels of Src family kinases such as Src and FAK in gastric cancer cells. In a previous study, saracatinib-sensitive colorectal cancer cells and explants were found to have increased activation of Src and FAK (11). Similar to this report, we found that the protein expression of phosphorylated Src (Y416) and FAK (Y861, Y397 and Y925) were elevated in the SNU216 and NCI-N87 cells (Fig. 1B) . We further compared the expression levels of various integrin family members (integrin α-2,-3,-5, and -V along with integrin β-1,-4,and -8) in different gastric cancer cells (data not shown). Among these, mRNA and protein levels of integrin β8 were highest in the saracatinib-sensitive SNU216 and NCI-N87 cell lines ( Supplementary Fig. 2 ). In order to determine whether saracatinib directly inhibits activity of Src family kinases (Src, Fyn, and Yes) and FAK, Western blotting was performed to measure the total and phosphorylated levels of these proteins following treatment with saracatinib. The phosphorylation of Src, Fyn, Yes, and FAK in both SNU216 and NCI-N87 cells was decreased by saracatinib (Fig. 1C) .
Because both sensitive cell lines (SNU216 and NCI-N87) were HER2 amplified cells, we tested whether HER2 amplification can be a marker for predicting sensitivity to Src inhibition.
However, other breast cancer cell lines in which HER2 were amplified (SKBR3, MDA-MB-453 and BT474) were resistant to saracatinib. We also compared protein expression levels of different integrin family members (integrin α-2,-3,-5,-V and integrin β-1,-4,-8), FAK and Src. Among these, integrin αv, integrin β-4,-8 and Src were highly expressed in the SNU216 and NCI-N87 cells compared to HER2-amplified breast cancer cells (Fig. 1D ). 
Src inhibition leads to blockage of the HER family and oncogenic signaling pathways
We next examined the activity of HER family and oncogenic (STAT3, AKT, and ERK) signaling pathways after treatment with saracatinib. EGFR has been reported to activate Src, and combined inhibition of Src and EGFR abrogate the growth of head and neck squamous cell carcinoma (20-21). Accordingly, decreased phosphorylation of HER family members and oncogenic signaling molecules such as AKT and ERK was detected in the SNU216 and NCI-N87 cells. In contrast, in SNU16 cells, p-HER2 was increased at a dose-dependent manner while no change in the phosphorylation of other molecules with the treatment of saracatinib. Additionally, saracatinib did not reduce STAT3 phosphorylation in the saracatinib-sensitive cell lines although STAT3 phosphorylation was increased in NCI-N87 cells following saracatinib treatment ( Fig. 2A and B) . Our findings were is consistent with those of previous reports showing that STAT3 is reactivated after Src inhibition, and combined inhibition of Src and STAT3 results in an improved response (22).
Saracatinib enhances antitumor effects of lapatinib in HER2-amplified gastric cancer cells
According to a previous report, increased Src activation confers resistance to trastuzumab and targeting Src in combination with trastuzumab sensitized trastuzumab-resistant cell lines (23). In addition, the integrin/FAK/Src pathway is highly activated in lapatinib resistant cells, and inhibition of these pathway overcomes lapatinib resistance (24).
We therefore co-treated cells with saracatinib and lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, to see if this combination enhances the effects on SNU216 and NCI-N87 cells. As shown in Saracatinib arrested SNU216 and NCI-N87 cells at the G1 phase, decreased cyclin D levels, and increased p27 expression ( Fig. 2A and B) . Furthermore, saracatinib markedly increased the sub-G1 phase fraction. PARP cleavage along with the activity of caspase-3 and caspase-7 were also stimulated in response to saracatinib (Fig. 3A and C) .
Bim (a pro-apoptotic BH3-only protein) has been reported to have an essential role in apoptosis. In an EGFR-mutant NSCLC, knocking down Bim expression leads to an attenuation of apoptosis induced by gefitinib (25-26). We therefore tested whether reduction of Bim expression affects on saracatinib-induced apoptosis in SNU216 and NCI-N87 cells. Both cell lines were transfected with Bim-specific or control siRNA. After 24 h, the cells were treated with saracatinib and the number of apoptotic cells was determined after 48 h with an annexin V assay. Bim was induced by saracatinib in a dose-dependent manner in the SNU216 and NCI-N87 cells (Supplementary Fig. 3 ).
The number of apoptotic cells was increased by Src inhibition; however, this number was significantly decreased by treatment with Bim-specific siRNA (Fig. 3D) . These data indicate that Bim induction contributes to saracatinib-induced apoptosis.
Saracatinib enhances the antitumor effects of chemotherapeutic agents in vitro and in vivo
We simultaneously treated 10 gastric cancer cell lines with saracatinib and 5-FU or cisplatin to determine whether saracatinib enhances the activity of these two chemotherapeutic agents which are commonly used to treat gastric cancer patients. Combined treatment with saracatinib and 5-FU or cisplatin produced synergistic effects in many of the gastric cancer cell lines even the cells were resistant to 5-FU or cisplatin alone (Table 2 ).
In NCI-N87 cells, one cell type in which the synergistic effects of saracatinib with 5-FU or cisplatin was observed, the number of apoptotic cells increased following the combined treatment of saracatinib and 5-FU or saracatinib and cisplatin (Fig. 4A ). 
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We next confirmed the in vivo efficacy of saracatinib alone, 5-FU alone or a combination of these two compounds in a N87 human gastric cancer xenograft model. Saracatinib alone showed significant antitumor activity, and the combination of saracatinib and 5-FU enhanced the individual antitumor activity of both drugs (Fig. 4B ). Tumors treated with saracatinib alone exhibited a significant decrease in cell proliferation. When the tumors were treated with combination of saracatinib and 5-FU, more decreases of cell proliferation and more increases of apoptosis were observed by Ki67 and TUNEL assay (Fig. 4C) . Furthermore, complete inhibition of Src/FAK activity was detected in the cells treated with a combination of these two drugs (Fig. 4D ). 
Discussion
Src is a mediator of numerous signal transduction pathways that are involved in many different steps of oncogenesis from proliferation to invasion and metastasis. Thus, targeting Src kinase for therapeutic purposes has been an important area of investigation. Blocking Src activity has antiinvasive and anti-migratory effects, and inhibits the growth of various types of cancer (4, 20, 27-28).
In the present study, we found that inhibiting Src with saracatinib had growth inhibitory effects on gastric cancer cells such as SNU216 and N87 cells (Table 1) . Furthermore, this compound exerted anti-migratory and anti-invasive effects on the SNU216 cells (Fig. 1A) .
There have been many efforts to identify predictive biomarkers for Src inhibitor. Potential markers predicting sensitivity to dasatinib, a multi-targeting inhibitor of tyrosine kinases that reduces the activities of c-Src, Bcr-Abl, and other kinases, were evaluated by gene expression profiling in a panel of 23 breast cancer cell lines. The results of this study have identified six genes that are highly correlated with dasatinib sensitivity (EPHA2, CAV1, CAV2, ANXA1, PTRF, and IGFBP2) (29). In addition, elevated expression of moesin, caveolin-1, and yes-associated protein-1 was found to be sensitive marker for dasatinib (30).
It has also been suggested that LRRC19 and IGFBP2 identified by the K-TSP classifier are potential predictive biomarkers for saracatinib sensitivity in pancreatic cancer (31). Furthermore, Src overexpression was suggested as genotype-associated indicator of sensitivity to Src inhibitor such as saracatinib and dasatinib in ovarian, breast, NSCLC or prostate cancers (32). A second K-TSP classifier (TOX>GLIS2, TSPAN7>BCAS4, and PARD6G>NXN) and increased activation of the Src pathway were also suggested to be predictive markers for saracatinib sensitivity in colorectal cancer (11). In the present study, we found that the levels of both Src (Y416) and FAK (Y861, Y397 and Y925) activity were elevated in SNU216 and NCI-N87 cells that are HER2 amplified, saracatinibsensitive cells (Table 1 and Fig. 1B) .
We next tested whether HER2 expression levels affect sensitivity to saracatinib. Given that saracatinib inhibited both Src/FAK and EGFR signaling pathways and lapatinib enhanced antitumor effects of saracatinib, we concluded that crosstalk may exists between Src and EGFR signaling.
Bim has been emerging as an essential component of the apoptotic process triggered by EGFR tyrosine kinase inhibition by gefitinib or lapatinib (25, 28). In our study, apoptosis observed with saracatinib accompanied by induction of Bim. Bim knockdown decreased the number of apoptotic cells following treatment with saracatinib. These findings suggest an important role of Bim induction in saracatinib-mediated apoptosis (Fig. 3D and Supplementary Fig. 3 ).
We also investigated the effects of combination treatment of saracatinib with 5-FU or cisplatin.
Saracatinib exerted synergistic effects in six of 10 gastric cancer cell lines in combination with 5-FU (Table 2) . A combination of saracatinib and 5-FU increased apoptosis in NCI-N87 cells (Fig. 4A ) and enhanced the antitumor activity of saracatinib in the NCI-N87 xenografts (Fig. 4B-D) . Previously, it was reported that Src inhibition reverts chemoresistance to 5-FU through thymidylate synthase (TS) regulation, and the effect of Src kinase inhibition on 5-FU chemosensitivity might be accomplished by blocking 5-FU-induced EGFR-AKT activation (39) . Therefore, we tested to see if the synergy between saracatinib and 5-FU observed in our study might have resulted from TS downregulation.
Saracatinib significantly decreased TS levels in NCI-N87 (Supplementary Fig. 5 ). Interestingly enough, SNU5 cells, which are resistant to 5-FU, also showed the synergism between saracatinib with 5-FU by downregulating TS (Supplementary Fig. 5 ).
Saracatinib also enhanced the efficacy of cisplatin in gastric cancer cell lines. One study found that Src activity mediates oxaliplatin (platinum-based chemotherapeutic agent) sensitivity and resistance, and reduced expression of Src leads to increased cytotoxicity in response to oxaliplatin (40) . Therefore, sensitivity to cisplatin and other platinum-based chemotherapeutic agents, might also be affected by altered Src expression or activity in a similar manner. Furthermore, since Src is a downstream target of multiple pathways including IGF-1R, EGFR, MET, and PDGFR, it is necessary to further investigate the effects of saracatinib on these various signaling pathways. 
In summary, our findings suggest that saracatinib shows antitumor effects in SNU216 and NCI-N87 cells through blockade of Src/FAK, HER family and oncogenic signaling pathways.
Saracatinib leads to G1arrest as well as apoptosis in association with induction of Bim. Intriguingly, saracatinib enhanced the effects of lapatinib. Furthernore, saracatinib enhanced the antitumor effects of cytotoxic agents such as 5-FU or cisplatin not only in saracatinib-sensitive cells but also in cells resistant to saracatinib. These preclinical data indicate that inhibition of Src kinase activity by saracatinib alone or in combination with other agents can be one of strategy to target gastric cancer. 
